AIM ImmunoTech Inc (NYSE American: AIM) is a biopharmaceutical company focused on the research, development, and commercialization of two primary drug candidates: Ampligen (rintatolimod), a TLR3 agonist immunotherapy, and Alferon N Injection, a natural interferon alpha. The company generates minimal product revenue, relying primarily on equity financing, including an at-the-market offering agreement with Maxim Group LLC for up to $3,000,000 in common stock sales as of April 1, 2025. AIM operates as a clinical-stage company with no meaningful commercial revenue base, funding operations through capital markets rather than product sales. Ampligen is under investigation across multiple indications including ME/CFS, pancreatic cancer, post-COVID conditions, Ebola virus disease (FDA Orphan Drug Designation granted November 2022), and Alzheimer's disease. Alferon N Injection is approved in Argentina under the brand name Naturaferon, with commercialization efforts ongoing pending regulatory renewal. The company holds a 5,210-square-foot R&D facility at the New Jersey Bioscience Center and an office in Riverton.

Revenue model

AIM ImmunoTech has no significant recurring product revenue. Operations are funded through equity issuances, including an at-the-market facility with Maxim Group LLC (up to $3,000,000 in common stock, established April 1, 2025). Limited product sales of Ampligen and Alferon N Injection exist but are not a material revenue source per the FY2025 10-K filed March 27, 2026.

Products and services

Ampligen (rintatolimod): investigational TLR3 agonist with clinical programs in ME/CFS, pancreatic cancer, post-COVID conditions, Ebola virus disease, and Alzheimer's disease. Alferon N Injection (Naturaferon in Argentina): natural interferon alpha product with ANMAT approval for sale in Argentina; approval renewal pending as of the FY2025 10-K.

Customers and end markets

End markets include patients with ME/CFS, pancreatic cancer, post-COVID conditions, Ebola virus disease, and Alzheimer's disease. Early access program patients in the Netherlands accessed Ampligen through myTomorrows. Argentine patients access Alferon N Injection through distribution partner Filaxis (formerly GP Pharm), though Filaxis has issued a termination notice for that project.

Value-chain role

AIM ImmunoTech is a drug developer and licensor. Fill and finish manufacturing for Ampligen is contracted to Pharmaceutics International Inc. Clinical research operations are managed through contract research organizations including Amarex Clinical Research LLC. Distribution of Alferon N Injection in Argentina was handled by GP Pharm, now Filaxis. Early access program services in Europe were managed by myTomorrows.

Geographic exposure

Primary operations in the United States, with R&D facilities in New Jersey and offices in Riverton. International exposure includes Argentina (Alferon N Injection/Naturaferon commercialization) and the Netherlands (Ampligen early access program via myTomorrows). Research collaborations with institutions in Italy (University of Cagliari) and Japan (National Institute of Infectious Diseases and Shionogi & Co., Ltd.).

Source: SEC 10-K, filed 2026-03-27

Industry: Biological Products, (No Diagnostic Substances) Peers: ABVC Biopharma Inc Ainos Inc Jasper Therapeutics Inc Oruka Therapeutics Inc Codiak BioSciences, Inc. Crescent Biopharma Inc Harpoon Therapeutics, Inc. Pasithea Therapeutics Corp